key: cord-0876994-dl3u07a4
authors: Chen, Jiangnan; Pan, Yong; Li, Gangfeng; Xu, Wenfang; Zhang, Lihong; Yuan, Shijin; Xia, Yan; Lu, Pei; Zhang, Jun
title: Distinguishing between COVID‐19 and influenza during the early stages by measurement of peripheral blood parameters
date: 2020-08-13
journal: J Med Virol
DOI: 10.1002/jmv.26384
sha: 0418bae4912061edbb46b0390813e6aefe2a0490
doc_id: 876994
cord_uid: dl3u07a4

Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 infection. This study aims to examine the changes in peripheral blood parameters during the early stages of COVID‐19 and influenza. We analyzed the peripheral blood parameters of 169 COVID‐19 patients and 131 influenza patients during the early‐onset stage. Results from the patients with COVID‐19 were compared with those from healthy controls and influenza patients. In addition, results from patients with common and severe COVID‐19 were further compared. There were significant differences between COVID‐19 and influenza patients in terms of age, white blood cell count, platelet count, percentage of neutrophils, percentage of lymphocytes, percentage of monocytes, percentage of eosinophils, percentage of basophils, neutrophil, count and monocyte count. Two parameters (monocyte count and percentage of basophils) were combined to clarify the diagnostic efficacy of COVID‐19 and influenza and the area under the curve was found to be 0.772. Comparison of peripheral blood parameters from common COVID‐19, severe COVID‐19, and influenza patients revealed many differences during the early disease stages. The diagnostic formula developed by this study will be of benefit for physicians in the differentiation of COVID‐19 and influenza.

or misdiagnosed. Our study explored changes in peripheral blood parameters of patients during the early stages of COVID-19 and influenza, and provides a reliable reference for better understanding the changes in laboratory test indicators of these patients as well as potential diagnostic markers for the COVID-19 disease. Republic of China. 5 Common cases were those who had a fever, respiratory tract symptoms, and pneumonia on imaging. Severe cases were those who had one of the following three clinical manifestations:

(a) shortness of breath with a respiratory rate greater than 30 breaths/min; (b) mean oxygen saturation ≤93% in the resting state;

and (c) partial pressure of arterial oxygen/oxygen concentration ≤300 mm Hg (1 mm Hg = 0.133 kPa). Severe cases also included the progressed of lesions by more than 50% within 24 to 48 hours, as detected by pulmonary imaging.

A total of 131 patients with influenza were also included in the present study. Of these, 78 patients had influenza A and 53 patients had influenza B. All influenza cases were confirmed by RT-PCR assay of nasal and pharyngeal swab specimens. The control group was subjected to tests including clinical examination, computed tomography, hepatitis B virus-DNA, anti-hepatitis C virus antibody, human immunodeficiency virus antigen and antibody tests, and RT-PCR for SARS-CoV-2, and the results of all tests were negative. The control group excluded respiratory diseases.

Peripheral blood from COVID-19 and influenza patients was collected at the hospitals as part of the first examination, and the parameters measured. The study was approved by the Ethics Committee of the Affiliated Hospital of Shaoxing University (IRB-AF-016-1.0). SPSS 19 .0 was used for statistical analyses. Continuous variables were expressed as mean (±standard deviation) or median (P25, P75), and were compared using an unpaired Student t test or the nonparametric Mann-Whitney test. Categorical variables were presented as counts and percentages, which were compared using χ 2 statistics or Fisher's exact test. Single-factor parameters (P < .05) were included in the multivariate logistic regression analysis and the regression equation was constructed based on multiple factors. The receiver operating characteristic (ROC) curve was used to evaluate the efficiency of diagnosing the disease stage of the patients. Statistical significance was defined as P < .05.

3.1 | Analysis of peripheral blood cell parameters from COVID-19 and influenza patients Table 1 lists the parameters measured in the peripheral blood of the COVID-19 and influenza patients. Of these, there were significant differences between COVID-19 and influenza patients in terms of age, the white blood cell (WBC) count, platelet (PLT) count, percentage of neutrophils (NE%), percentage of lymphocytes (LY%), percentage of monocytes (MO%), percentage of eosinophils (EO%), percentage of basophils (BA%), neutrophil count (NE#), and monocyte count (MO#).

A multivariate analysis was performed to obtain the regression formula. Using stepwise forward logistic regression analysis, we found that two variables (MO# and BA%) were independently related to COVID-19 (Table 2) . Then, the logistic regression equation was used to calculate the following formula: On the basis of ROC curve (Figure 1 ), the best cutoff point for the joint probability was found to be 0.45, the diagnostic sensitivity was 71.6%, and the specificity was 74.8%. Therefore, COVID-19

should be considered as the diagnosis when the joint probability is greater than 0.45, while influenza should be considered when the joint probability is less than 0.45.

The average age and the proportion of men in the severe COVID-19 group were older and greater, respectively, than in the common COVID-19 and influenza groups. Lymphocyte count (LY#) and eosinophil count (EO#) of the severe COVID-19 group were significantly lower than in the common COVID-19 and influenza groups. The PLT count of the severe COVID-19 group was significantly lower than that of the common COVID-19 group. MO%, MO#, and NE# of the influenza group were significantly higher than in the severe and common COVID-19 groups. LY%, EO%, and BA% of influenza and severe COVID-19 groups were significantly lower than in the common COVID-19 group. NE% of influenza and severe COVID-19 groups were significantly higher than in the common COVID-19 group.

During the early stages of the disease, male sex, higher age, and lower lymphocyte, eosinophil, and basophil levels predicted that the COVID-19 disease was more likely to be a severe case. .000

.299

.000

.000

. .000

.000

.359

.047

.002

Note: Data were expressed as mean (SD), medians (P25, P75), or N (% Comparison between severe and influenza groups.

COVID-19 were significantly lower than in the control group (P < .001). NE% of COVID-19 was significantly higher than that of the control group (P < .001).

The WBC count in the influenza group was higher than in the severe and common COVID-19 groups, and the proportion of WBC count in the influenza group that was above the upper limit of the reference interval (9.2%) was higher than that of the common (0.7%) and severe COVID-19 (0%) groups ( Table 3 ). The abnormal rates of NE%, LY%, and EO% in influenza and severe COVID-19 groups were significantly higher than in the common COVID-19 group. The percentages of LY% in influenza and severe COVID-19 groups that were below the lower limit of the reference interval were 55.7% and 54.2, respectively, which were higher than in the common COVID-19 group (24.1%). The proportion of EO% in the severe COVID-19 group (62.5%) that was lower than the lower limit of the reference interval was higher than in influenza (45.8%) and common COVID-19 (21.4%)

groups. The proportion of EO# in the severe COVID-19 group (58.3%) that was lower than the lower limit of the reference interval was higher than in influenza (40.5%) and common COVID-19 (22.1%)

groups. The proportion of LY# in the severe COVID-19 group (79.2%) that was lower than the lower limit of the reference interval was higher than in influenza (52.7%) and common COVID-19 (40%)

groups. The proportion of MO# in the influenza group (36.6%) that was higher than the upper limit of the reference interval was significantly higher than in the severe (4.2%) and common COVID-19 (6.2%) groups. (Figure 2 ).

During the early stage of COVID-19 disease, lower albumin (ALB) and higher C-reactive protein (CRP), lactate dehydrogenase (LDH), gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), and creatine kinase (CK) predicted that it was more likely to develop into severe COVID-19 disease. Table 4 shows that the concentrations of total protein (TP), ALB, globulin, alkaline phosphatase, total bilirubin, blood urea nitrogen, and total cholesterol of patients in the early stages of COVID-19

were significantly lower than those of the control group, whereas the concentrations of AST, serum creatinine, CK, CK-myocardial band, LDH, and CRP were significantly higher than in the control group (P < .05). The ratio of ALB in the COVID-19 group above the upper reference limit was 0%. TP and ALB concentrations in the severe COVID-19 group were significantly lower than in the common group, and the proportion of the ALB in the severe COVID-19 group that was lower than the reference lower limit was 58.3% compared to 29.0% for the common COVID-19 group.

Alanine aminotransferase (ALT), AST, GGT, CK, LDH, and CRP concentrations in the severe COVID-19 group were significantly higher than in the common COVID-19 group. The ratios of CRP, LDH, GGT, and AST in the severe COVID-19 group that were above the reference upper limit were 87.5%, 62.5%, 50.0%, and 45.8%, respectively, which were significantly higher than in the common COVID-19 group, being 45.5%, 21.4%, 20.7%, and 15.2%, respectively (Table 5 ). 13, 14 In this study, patients with COVID-19 also showed significantly lower PLT counts, and the PLT count of severe COVID-19 patients was significantly lower than that of common COVID-19 and influenza patients. PLT count is an independent risk factor for COVID-19. 15 This study also found that the severe COVID-19 group was older and had a higher percentage of men than that of the common COVID-19 and influenza groups. The age of the patient can be related to the prognosis of the disease. 16 Previous studies have shown that men are more susceptible to SARS-CoV-2 and have a higher mortality rate, which is related to endogenous testosterone. 17 Studies have shown that liver injury is common in patients with COVID-19 18 and autopsy results of patients with COVID-19 have shown hepatocyte degeneration, neutrophil infiltrating focal necrosis, lymphocytes and mononuclear cells in the hepatic lumen area, cell infiltration, and microthrombosis. Liver injury is associated with longer hospital stays and may be related to the prognosis of patients with COVID-19. Some COVID-19 patients without a history of liver disease are found with a liver injury before using any medication. 19 This study showed that during the early stage of the disease, the TP and ALB in the severe COVID-19 group were lower than in the common COVID-19 group, whereas the CRP, GGT, ALT, and AST were significantly higher. These indicators are significant in their ability to predict, in the early stage of the disease, patients who will develop severe COVID-19. During the early stage of COVID-19, LDH and CK in the severe COVID-19 group were significantly higher than in the common COVID-19 group. The decreases of LDH and CK in serum are related to the elimination of viral messenger RNA (mRNA), with the COVID-19 viral mRNA clearance time positively correlated with a hospital stay. Decreases in LDH and CK may indicate a good prognosis for COVID- 19. 20 In summary, COVID-19 and influenza can cause different changes in peripheral blood parameters, which should be considered in the early stages of COVID-19 and influenza. The diagnostic formula developed in this study should help us to enable differentiation of COVID-19 and influenza during their early stages.

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Longitudinal change of SARS-CoV2 antibodies in patients with COVID-19

Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2

National Health Commission of the People's Republic of China. Diagnosis and treatment protocols of the novel coronavirus pneumonia (trial version 7)

A novel coronavirus from patients with pneumonia in china

Can we reduce mortality of COVID-19 if we do better in glucose control?

Flu Season: Preliminary Burden Estimates | CDC

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Diverse and unexpected roles of human monocytes/ macrophages in the immune response to influenza virus

Impaired cellular immune responses during the first week of severe acute influenza infection

Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression

Magnitude to thrombocytopenia among the patients with novel Middle East respiratory syndrome

Hematological findings in SARS patients and possible mechanisms (review)

Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count

The management of coronavirus disease 2019 (COVID-19)

SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): a multidimensional research project

Liver injury during highly pathogenic human coronavirus infections

Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study

The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients

Distinguishing between COVID-19 and influenza during the early stages by measurement of peripheral blood parameters

This study was supported by the Science Technology Bureau of Shaoxing (Grant No. 2018C30017). None of the funders had any role in the study design or in the collection, analysis, and interpretation of data, or in the writing of the article and the decision to submit it for publication. The researchers confirm their independence from funders and sponsors.

The authors declare that there are no conflict of interests. 

Research data are not shared.

http://orcid.org/0000-0002-1041-9927